Which company produces Cemiplimab and its background?

Cemiplimab is a humanized IgG4 type PD-1 monoclonal antibody developed by Regeneron Pharmaceuticals) and French pharmaceutical giant Sanofi (Sanofi) are jointly developed. As an immune checkpoint inhibitor, this drug mainly blocks the binding of PD-1 (programmed death receptor) and its ligand PD-L1, thereby enhancing the ability of T cells to attack tumor cells and improving the patient's immune response. Cimepilimab was first approved in the United States in 2018 and is the world's first PD-1 antibody drug approved for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC).

The research and development of cimipilimab is one of the important breakthroughs of Regeneron in the field of immuno-oncology treatment. The company was previously known for its development of ophthalmic drugs Eylea, and its cooperation with Sanofi marks its key entry into the tumor immunotherapy market. Cimepilimab initially showed significant efficacy in patients with CSCC in clinical trials, providing a new treatment option especially when traditional treatment methods are ineffective.

The scope of indications of this drug were subsequently expanded to include patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), especially among those with high PD-L1 expression levels and who are not suitable for chemotherapy, becoming an optional first-line immunotherapy option. In addition, cimepilimab has also conducted active clinical research in multiple indications such as melanoma and cervical cancer, laying the foundation for its market expansion.

Up to now, cimepilimab has been approved for marketing in many countries such as the United States and Europe, but it has not yet widely entered the market in mainland China. Due to its good efficacy and safety, it has gradually established its position in the field of immunotherapy, especially in rare indications such as skin cancer, with strong clinical competitive advantages. In the future, with the approval of more indications and the exploration of combination therapy with other immune drugs or targeted drugs, cimepilimab is expected to occupy a place in the global anti-cancer drug market.

Reference materials:https://www.libtayohcp.com/